PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
Fading2 outlets reported this in 4 reports over 2 days - a further 2 reports reprinted copy already published elsewhere
original reportingcopies
Thu, 15 October 2026peak 3 reports on Thu, 15 October 2026Sat, 24 October 2026
What it is about
Christian MarcouxJessica CohenRichard HarbinsonEmil IvanovNational Survey Of Children HealthBewleyInsights Of Bullying At SchoolDrug AdministrationR D CommunicationsEuropean Medicines AgencyPediatric Dermatology Research Alliance Pedra Annual ConferenceUnited StatesCorporate CommunicationsCalifornia, United StatesSwitzerlandJapanDrei JahreSteigende AnleiherenditenNemluvio European Medicines AgencyPfizer
Who published it, and when
original reportcopyfirst to report
theobserver.ca
northernnews.ca
finanznachrichten.de
15 Oct, 05:04over 2 hours15 Oct, 07:06
1 report left out of the cascade - too little in common with the story to place
How it spread - 2 original reports, 2 reprints
Thu, 15 October 2026
1 report- finanznachrichten.de07:06first to report
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved
2 reprints
- theobserver.ca15 Oct, 05:04their copy
- northernnews.ca15 Oct, 05:05their copy
Sat, 24 October 2026
1 report- hcplive.com00:56
Sarina Berger Elmariah, MD, PhD, MPH, reviews 3-year nemolizumab data showing deeper skin clearance and lasting itch relief in atopic dermatitis responders.